Anthem Biosciences Limited , a prominent player in the biosciences sector, has announced the appointment of Ms. Divya Prasad as its Company Secretary and Compliance Officer. The appointment, which took effect on October 18, 2024, marks a significant addition to the company's leadership team.

Key Appointment Details

Ms. Prasad, who holds ICSI Membership No: A41438, brings her expertise to this crucial role within the organization. Her responsibilities include ensuring compliance with various regulatory requirements and overseeing the company's secretarial functions.

Dual Role and Responsibilities

In addition to her position as Company Secretary, Ms. Prasad will also serve as the Compliance Officer under the Securities and Exchange Board of India (SEBI) listing regulations. This dual role underscores Anthem Biosciences Limited's commitment to maintaining high standards of corporate governance and regulatory compliance.

Company Background

Anthem Biosciences Limited, formerly known as Anthem Biosciences Private Limited, is a listed entity on both major Indian stock exchanges.

Regulatory Compliance

In line with regulatory requirements, Anthem Biosciences Limited has taken steps to ensure transparency and compliance:

• The company has appointed KFin Technologies Limited as its Registrar & Share Transfer Agent, in accordance with regulation 7(1) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
• A structured digital database is maintained to record details of individuals with whom unpublished price-sensitive information is shared, as per SEBI regulations.
• The company has implemented a Code of Conduct to regulate, monitor, and report trading by its employees and other connected persons, effective from December 14, 2025.

Trading Window Closure

As part of its commitment to preventing insider trading, Anthem Biosciences Limited has announced the closure of its trading window for all Directors, Designated Persons, and other individuals covered under the company's Code of Conduct. The trading window will remain closed from July 21, 2025, until 48 hours after the declaration of financial results for the quarter ended June 30, 2025.

The appointment of Ms. Divya Prasad and the implementation of these regulatory measures reflect Anthem Biosciences Limited's dedication to maintaining high standards of corporate governance and regulatory compliance in its operations.

Anthem Biosciences Limited made a strong debut on the stock market, with its shares opening at ₹723.05, marking a significant premium of 27% over its initial public offering (IPO) price of ₹570 per share.

Impressive Market Entry

The biosciences company's stock commenced trading on a high note, reflecting robust investor interest in the newly listed entity. This strong opening performance underscores the positive sentiment surrounding Anthem Biosciences Limited and its potential in the market.

IPO Details

Anthem Biosciences Limited had set its IPO price at ₹570 per share. The substantial gap between the issue price and the opening price of ₹723.05 represents a gain of ₹153.05 per share for investors who were allotted shares in the IPO.

Market Response

The impressive listing suggests that market participants have shown confidence in Anthem Biosciences Limited's business model and growth prospects. The biosciences sector has been gaining attention, and Anthem's strong market debut may be indicative of the broader interest in this industry.

Investor Outlook

While the initial response has been positive, it's important for investors to note that stock prices can be volatile, especially in the early days of trading. Market analysts will be closely watching the stock's performance in the coming days to gauge its stability and long-term potential.

Anthem Biosciences Limited's successful listing adds to the recent trend of well-received IPOs in the Indian stock market, particularly in the healthcare and life sciences sectors. As the company begins its journey as a publicly traded entity, stakeholders will be keen to see how it leverages this positive start to fuel its growth and expansion plans.